Takeda reports five-year overall survival data for ADCETRISs demonstrating durable remissions in relapsed / refractory hodgkin lymphoma

Takeda UK Ltd has announced post-treatment follow up data from the pivotal phase 2 study of single-agent brentuximab vedotin for the treatment of relapsed or refractory Hodgkin lymphoma following… Source link